Department of Electrophysiology, University Heart Center Lübeck, Medical Clinic II, University Hospital Schleswig-Holstein, Ratzeburger Allee 160, 23538, Lübeck, Germany.
Vivantes Klinika Am Urban und im Friedrichshain und Universitäres Herzzentrum Rostock, Rostock, Germany.
Clin Res Cardiol. 2022 May;111(5):522-529. doi: 10.1007/s00392-021-01878-z. Epub 2021 Jun 9.
To compare patient characteristics, safety and efficacy of catheter ablation of supraventricular tachycardia (SVT) in patients with and without structural heart disease (SHD) enrolled in the German ablation registry.
From January 2007 until January 2010, a total of 12,536 patients (37.2% with known SHD) were enrolled and followed for at least one year. Patients with SHD more often underwent ablation for atrial flutter (45.8% vs. 20.9%, p < 0.001), whereas patients without SHD more often underwent ablation for atrioventricular nodal reentrant tachycardia (30.2% vs. 11.8%, p < 0.001) or atrioventricular reentrant tachycardia (9.1% vs. 1.6%, p < 0.001). Atrial fibrillation catheter ablation procedures were performed in a similar proportion of patients with and without SHD (38.1% vs. 36.9%, p = 0.21). Overall, periprocedural success rate was high in both groups. Death, myocardial infarction or stroke occurred in 0.2% and 0.1% of patients with and without SHD (p = 0.066). Major non-fatal complications prior to discharge were rare and did not differ significantly between patients with and without SHD (0.5% vs. 0.4%, p = 0.34). Kaplan-Meier mortality estimate at 1 year demonstrated a significant mortality increase in patients with SHD (2.6% versus 0.7%; p < 0.001).
Patients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients. These data highlight the safety and efficacy of SVT ablation in patients with and without SHD. Nevertheless Kaplan-Meier mortality estimates at 1 year demonstrate a significant mortality increase in patients with SHD, highlighting the importance of treating the underlying condition and reliable anticoagulation if indicated.
比较德国消融注册中心纳入的伴结构性心脏病(SHD)和不伴结构性心脏病(SHD)的室上性心动过速(SVT)患者的患者特征、安全性和疗效。
从 2007 年 1 月至 2010 年 1 月,共纳入 12536 例患者(37.2%已知有 SHD),并至少随访 1 年。SHD 患者更常接受消融治疗房扑(45.8% vs. 20.9%,p<0.001),而无 SHD 患者更常接受消融治疗房室结折返性心动过速(30.2% vs. 11.8%,p<0.001)或房室折返性心动过速(9.1% vs. 1.6%,p<0.001)。有 SHD 和无 SHD 的患者行心房颤动导管消融术的比例相似(38.1% vs. 36.9%,p=0.21)。总的来说,两组患者的围手术期成功率均较高。有 SHD 和无 SHD 的患者死亡、心肌梗死或卒中的发生率分别为 0.2%和 0.1%(p=0.066)。在出院前发生的主要非致死性并发症很少,两组间无显著差异(0.5% vs. 0.4%,p=0.34)。1 年 Kaplan-Meier 死亡率估计显示,有 SHD 的患者死亡率显著增加(2.6% vs. 0.7%;p<0.001)。
尽管 SHD 患者的基线特征不利,但接受 SVT 消融的有 SHD 和无 SHD 患者的成功率和主要并发症发生率相似。这些数据突出了 SVT 消融在有 SHD 和无 SHD 患者中的安全性和疗效。然而,1 年 Kaplan-Meier 死亡率估计显示,有 SHD 的患者死亡率显著增加,这突出了治疗潜在疾病和在必要时可靠抗凝的重要性。